← Back to Search

NavDx(R) Blood Test for Gynecologic Cancers

N/A

Recruiting

Research Sponsored by Northwell Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8-12 weeks

Awards & highlights

Study Summary

This trial will test a simple blood test to detect HPV-related gynecologic cancers and pre-cancerous tumors, which could help diagnose and monitor these conditions more easily.

Who is the study for?

This trial is for individuals over 18 years old who have been diagnosed with high-grade cervical dysplasia or invasive cervical cancer related to HPV. It's not open to those who don't meet these specific conditions.Check my eligibility

What is being tested?

The study is testing NavDx(R), a blood test designed to detect fragments of tumor-specific DNA from HPV-associated cancers using advanced PCR techniques, aiming to distinguish between pre-invasive and invasive cervical cancers.See study design

What are the potential side effects?

As this trial involves a non-invasive blood test, there are minimal expected side effects. However, common risks associated with blood draws may include pain at the injection site, bruising, or bleeding.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 8-12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~8-12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 8-12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

On-Treatment Circulating HPV DNA

Post-Treatment Circulating HPV DNA

Pre-Treatment Circulating HPV DNA

Trial Design

1Treatment groups

Experimental Treatment

Group I: Circulating HPV DNAExperimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

NaverisUNKNOWN

2 Previous Clinical Trials

126 Total Patients Enrolled

Northwell HealthLead Sponsor

460 Previous Clinical Trials

470,943 Total Patients Enrolled

Media Library

Circulating HPV DNA Clinical Trial Eligibility Overview. Trial Name: NCT05606133 — N/A

Cervical Cancer Research Study Groups: Circulating HPV DNA

Cervical Cancer Clinical Trial 2023: Circulating HPV DNA Highlights & Side Effects. Trial Name: NCT05606133 — N/A

Circulating HPV DNA 2023 Treatment Timeline for Medical Study. Trial Name: NCT05606133 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any remaining openings in this clinical research initiative?

"Affirmative, clinicaltrials.gov records attest that this research endeavour is actively seeking participants. It was first announced on August 10th 2022 and has since been modified as recently as October 31st 2022. One health facility will be recruiting a total of 100 patients for the trial."

Answered by AI

To what extent is enrollment available for this clinical trial?

"Affirmative. Perusal of the information hosted on clinicaltrials.gov elucidates that this medical experiment, which was initially posted on August 10th 2022, is presently recruiting patients. Approximately 100 individuals must be recruited at a single institution."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers

Elena Pereira 2022. "Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05606133.